Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Dec
26
Today In Oncology
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers
Deb Schrag Elected 2027–2028 ASCO President
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo